However though both trials are negatives, and didn't show any benefit of adding cetuximab to FOLFOX in term of DFS for resected stage III CC, no detrimental effect of the FOLFOX + cetuximab combination therapy was observed even in patients with KRAS mutated tumors.
We selectively reviewed a number of recent trials in order to identify why the trials were negative.
The BLT (Waller et al., 2004) and the ALPI (Scagliotti and Novello, 2003) trials were negative.
Antibiotics are generally recommended for acute bacterial sinusitis but two of the four placebo controlled clinical trials were negative.
Despite initial enthusiasm based on preclinical and phase II clinical studies, subsequent phase III randomized controlled trials were negative.
Early retrospective studies of statins suggested that the progression of AS could be delayed, but subsequent larger randomized trials were negative, underlining the importance of prospective trials.
However, in cancer molecular targeting therapy, the results of Gefitinib clinical trials were negative initially because none of these trials selected patients based on their EGFR kinase dependence.
As most positive trials (5/9) showed benefits for only one parameter, while the other trials were negative (4/9), the overall benefits seem limited.
Large randomized clinical trials were negative for increased breast cancer risk with glargine, but longer follow up may be needed to detect delayed or smaller effects.
